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Abstract The therapy of type 1 diabetes is an open
challenging problem. The restoration of normoglycemia
and insulin independence in immunosuppressed type 1
diabetic recipients of islet allotransplantation has shown the
potential of a cell-based diabetes therapy. Even if success-
ful, this approach poses a problem of scarce tissue supply.
Xenotransplantation can be the answer to this limited donor
availability and, among possible candidate tissues for
xenotransplantation, porcine islets are the closest to a future
clinical application. Xenotransplantation, with pigs as
donors, offers the possibility of using healthy, living, and
genetically modified islets from pathogen-free animals
available in unlimited number of islets. Several studies in
the pig-to-nonhuman primate model demonstrated the
feasibility of successful preclinical islet xenotransplantation
and have provided insights into the critical events and
possible mechanisms of immune recognition and rejection
of xenogeneic islet grafts. Particularly promising results in
the achievement of prolonged insulin independence were
obtained with newly developed, genetically modified pigs
islets able to produce immunoregulatory products, using
different implantation sites, and new immunotherapeutic
strategies. Nonetheless, further efforts are needed to
generate additional safety and efficacy data in nonhuman
primate models to safely translate these findings into the
clinic.
Keywords Type 1 diabetes.Islet xenotransplantation.
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Introduction
In the year 2000 the Edmonton protocol proved that clinical
pancreatic islet allotransplantation (alloTx) can be success-
fully performed to treat type 1 diabetes (T1D) using a
steroid-free immunosuppressive regimen [1]. Even if islet
replacement could be considered a preferable alternative to
insulin therapy in long-term diabetic patients, this thera-
peutic option will be practically limited by the number of
islet donors that will never be sufficient. A possible solution
to the problem of tissue supply may be found by
investigating the potential of embryonic as well as induced
pluripotent stem cells to generate functional insulin-
producing cells. Clinical applications await successful
testing in animal models. Alternatively, xenotransplantation
(xenoTx) of pig islets is currently the most advanced and
appealing approach with respect to a possible clinical
application [2]. Pigs are the best candidates as human
substitutes [3] for several reasons: pig insulin differs from
human insulin by just one amino acid; pig islets have lower
sensitivity to destruction by recurrent T1D autoimmunity
than human islets [4], they do not accumulate amyloid [5],
and pig donors can be genetically modified to improve
immunomodulation and cytoprotection of pig islets. The
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primates xenoTx are more encouraging than those obtained
using pig whole organs, which makes their employment
predictable in clinical trials in the next few years [6￿￿]. To
make this technique a clinically feasible treatment option
we need to generate more convincing preclinical data in the
pig-to-primate xenoTx model.
Rationale for Pig Islet XenoTx
Clinical human islet transplantation is emerging as a suitable
therapeutic option in T1D patients with uncontrollable
glycemic management limited by hypoglycemia unawareness
and effective hormonal counter-regulation [7, 8]. Improving
the islet processing techniques and introducing new immuno-
modulatory strategies, we expect to increase the benefit/risk
ratioofhumanisletalloTx.However,thediscrepancybetween
the number of potential islet recipients (ie, patients with T1D
withfrequentepisodesofseverehypoglycemia andthosewith
devastatingmicrovascular diabetescomplications)[9] and the
number of available donors remains the major crucial issue
to be solved, before a broader use of islet transplantation
might become a reliable clinical alternative [1].
Pig islet xenoTx currently represents a very promising
solution to the limited donor supply [10]. It is important to
underline that pig islets might have different additional
distinct advantages over human islets for this purpose. First,
the quality of prepared pig islets from a pig donor is
consistently higher than human islets from a deceased
donor (no comorbidity, senescence, brain death, and cold
ischemia injury). Second, porcine islet xenografts may be
resistant to destruction by recurrent autoimmunity [11].
Third, the risk of infectious disease transmission associated
with xenoTx of pancreatic islets is lower than the one
observed in human islet alloTx. Furthermore, it is possible
to induce donor-specific immunologic hyporesponsiveness
pretreating the recipient with donor antigen(s) [12] or using
genetically modified pig islets with the overexpression of
genes encoding cytoprotective and immunomodulatory
molecules [13].
Pig Islet Source, Isolation, and Preparation
In human islet alloTx, an average of 10,000 human islet
equivalents (IEQ)/kg of recipient body weight are consid-
ered necessary to achieve insulin independence [1]. There is
not a consensus for their minimal number in xenoTx [14].
Different groups have proposed islet numbers in the range
of 25,000 to 85,000 IEQ/kg of body weight as the
requirement to achieve blood glucose normalization in
diabetic non-human primates (NHPs) with either neonate or
adult pig islets [15￿, 16, 17]. Pig fetal or neonatal islet-like
clusters are easy to isolate, but require a period of several
weeks to mature into glucose-sensing and insulin-producing
cells [18]. The immature cells are more resistant to
inflammation and ischemia, and endure the engraftment
process better than adult islets. The major advantage of the
islet transplantation using islets isolated from adult pigs
[18] is that graft function can be achieved and monitored
immediately after transplantation.
Fetal Islets
The isolation of fetal islets requires relatively easy techniques
[19]. Because of the limited amount of exocrine tissue,
isolation can be completed just using a simple mixture of
exogenous digestive enzymes. Pure islet-like cell clusters
(ICCs), also called proislets, can be obtained by simple
culture without any technical purification step [19]. Howev-
er, even if ICCs can normalize blood glucose levels in
rodents, several studies have shown that ICCs have poor
insulin response to glucose for relatively long periods [20].
Fetal islets are more resistant to ischemic injuries consequent
to pancreas procurement, probably due to the relative lack of
exocrine tissue retained within ICCs and also for other
various characteristics typical of fetal tissue itself [19].
Putative precursor cells, located in the pancreatic ducts or
among the ICCs, allow for proliferation after transplantation.
Even fetal porcine pancreas fragments have the potential to
grow, mature, and function normally when transplanted in a
neovascularized site [21].
As previously mentioned, perhaps the major disadvantage
of fetal islets is their immaturity, which is associated with
delayed functionality: it may take over 2 months before
achieving blood glucose normalization in in vivo transplan-
tation experiments [22] and, during this period, there is a
poor insulin response to glucose. A second disadvantage is
t h eh i g he x p r e s s i o no fα-1,3-galactose (Gal) on the surface
of the fetal pig islets—the sugar responsible for hyperacute
rejection—which renders those islets more susceptible to
rejection than adult pig islets, which, in contrast, express
little Gal [23]. Due to the size of the fetal pancreas, only
relatively small numbers of ICCs can be obtained, posing an
ethical problem on how many fetuses may be necessary to
normalize glycemia in diabetic NHPs, let alone humans.
Unless better ways to increase the β-cell numbers in vitro
become available, it is necessary to use tens of pig fetuses to
restore normoglycemia in a patient.
Neonatal Islets
Neonatal pig islets (NPIs) (ie, islets obtained from piglets
aged 1–5 days) can be easily procured and isolated by
enzymatic digestion [24]; freshly isolated NPIs consist only
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exocrine cells represents approximately 74% of the cell
pool. During in vitro culture, however, acinar cells undergo
apoptosis leading to enrichment of the endocrine compo-
nent (35% after 9 days of culture) and of the pool of
nongranulated epithelial cells [24]. During in vitro culture
NPIs, and more specifically β cells, proliferate, as indicated
by studies of bromodeoxyuridine (BrdU) incorporation over
time [25]. Interestingly, BrdU incorporation shows two
higher peaks: initially after isolation and around days 9 to
12, when the cell cluster assume an islet-like morphology
[25]. Neonatal pig β cells are more responsive to glucose
than fetal pig β cells are [24] but yet not as fully functional
as adult cells. The process of maturation of the secretory
machinery in neonatal pancreatic islets involves cell-to-cell
contact, expression of gap and adherence junctional
proteins, and can be accelerated by prolactin [26]. After
transplantation in immunodeficient mice the β-cell mass of
NPIs increases up to 20 times further, confirming that β
cells proliferate and/or that epithelial precursor cells
differentiate into β cells [24]. Although insulin secretion
is also delayed after transplantation, the maturation period
is generally shorter than after fetal islet transplantation.
NPIs express xenoantigens, such as human-serum
stained epitopes and IB4 (eg, Gal) epitopes but also other
undefined xenoantigens [25], with potential relevance for
possible clinical improved treatments. The availability of α-
1,3-Gal knockout (GT-KO) pigs as a source of neonatal islet
cells can therefore prove useful to attenuate, although not
completely abrogate, the problem of hyperacute rejection.
Neonatal islets from 1- to 5-day-old piglets do not differ
substantially from 1-month-old piglet islets, showing a
similar response to glucose stimulation in vitro during
incubation, as well as comparable β-cell mass and function,
and can therefore be considered a valid alternative source of
islets to adult ones.
The advantage of using neonatal over fetal pig islets
consists of the possibility of preventing the sow from
undergoing surgery necessary for the fetus harvesting. The
number of ICCs isolated from the neonatal pig pancreas is
not significantly different than that of fetal ICCs, leaving
yet unresolved the problem of supply, thus the need for
numerous neonatal pigs to treat an NHP or a patient.
Adult Islets
In contrast to fetal and neonatal islets, adult porcine islets
(pig donor age >6 months), due to their mature status, start
functioning immediately following isolation and transplan-
tation [27]. Their immunogenicity, despite a low expression
of Gal, is highly variable and the technique for their
isolation rather difficult. The isolation outcome varies and
the effects/damage of isolation can influence their func-
tional performance following transplantation [28]. In adult
pigs, the peri-insular matrix is poorly developed; this makes
islets susceptible to fragmentation and, consequently, cell
breakage during the isolation process. Generally, retired
breeders (sows that underwent multiple pregnancies) are
preferred as pancreas donors, providing islets with a more
compact shape and more resistant to isolation and culture.
One adult pig pancreas can provide a sufficient quantity of
functional islets to perform xenoTx in one or two NHPs. In
contrast to fetal and neonatal islets, β cells from adult pigs
are able to respond to hyperglycemia within hours after
transplantation. However, several studies reported low
insulin secretion even from isolated adult pig islets [18,
29]. The poor insulin secretion of isolated pig islets in vitro,
however, does not necessarily imply a lack of function in
vivo. Published data show that both isolated neonatal and
adult pig islets have been able to correct diabetes in NHPs
[15￿, 16, 17].
Isolation and Preparation
Pancreata are recovered during a non-survival surgical
procedure. Concerning fetuses and neonates pancreatic
organs, these are dissected immediately after exsanguina-
tion and euthanasia of the piglet. Retained blood in the
tissue reduces islet yield, possibly because of inhibition of
the collagenolytic activities of the digestive enzymes; for
this reason, extensive flushing of the organ before, during,
and directly after pancreatectomy is necessary. In adult pigs
the pancreas is harvested with a technique similar to the one
utilized to harvest the pancreas from deceased organ donors
[30]. Islet viability is strongly influenced by warm and cold
ischemia time, the isolation process, and the period of
storage, but it is difficult to evaluate the exact influence of
each factor [26, 31]. Warm ischemia must be kept as
minimal as possible to avoid autolysis of the pancreas by
proteolytic and lipolytic enzymes [31]. In adult pancreata,
intraductal injection with collagenase solution early after
pancreas dissection (before its cold preservation) seems to
contribute to a higher islet yield; however, collagenase is
commonly injected intraductally after cold preservation,
just before the isolation begins [31].
Since the introduction of an efficient method for the bulk
isolation of pig pancreatic islets by Ricordi et al. [18], most
groups use a similar, semiautomatic isolation method also
for pig islets. The pancreas, following collagenase injec-
tion, is mechanically disrupted in a digestive chamber under
controlled temperature [26]. Continuous exposure of the
tissue to digestive enzymes is necessary, but it is important
to avoid overexposure and damage to the islets. The
enzymatic/mechanical digestion is followed by a purifica-
tion step, thus the separation of the porcine islets from the
exocrine tissue. The standard method for islet purification is
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tage of the fact that islets have a lower density than
exocrine tissue. Usually a purity of 70% to 90% (islets/
whole tissue) is efficiently obtained with various, equally
valid, gradient types [31]. For fetal and neonatal islets a
culture time of several days is required to facilitate cell
re-aggregation and to eliminate the exocrine cells [32].
However, adult pig islets seem to be more fragile than fetal
and neonatal ICCs during culture, and loss of islet mass and
viability are observed over time. Short-term culture is
therefore desirable for adult islets. Typical functional assays
to assess the functionality of the isolated islets include in
vitro glucose-stimulated insulin release tests, and in vivo
function determined by transplanting islets into small
diabetic, immunodeficient rodents, such as nonobese
diabetic/scid mice [31].
Induction of Diabetes in NHPs
Studies in the pig-to-NHPs islet xenoTx model are needed
to provide evidence of safety and efficacy prior to clinical
phase 1 and 2 trials. To meet these criteria, preclinical
studies should be performed in diabetic NHPs; to obtain
these, three different approaches have been used. Sponta-
neous diabetes, reported in several strains of monkeys
including cynomolgus, is usually associated with age,
obesity, β-cell degeneration, and extensive amyloid depo-
sition [33]; the availability of these monkeys is limited, and
their diabetes could not be considered as a faithful T1D
model. Surgical pancreatectomy is a second option, but its
execution is difficult and it has associated morbidity
problems. This technique is probably the most convincing
in the generation of irreversible diabetes, but pancreatecto-
my needs to be total to avoid potential residual function and
possibly β-cell regeneration, and it has the disadvantage of
eliminating the endogenous exocrine pancreatic function.
The third approach currently used is chemical induction of
hyperglycemia through streptozotocin (STZ) [34]. STZ is a
compound derived from the bacterium Streptomyces
achromogenes with the ability to selectively destroy β
cells by DNA damage and nicotinamide adenine dinucleotide
depletion [34]. Its intravenous administration successfully
achieves killing of β cells and subsequent induction of
hyperglycemia, but a discussion on the optimal dose remains
an open problem.
A single dose of 30 mg/kg of STZ is not sufficient to
induce complete diabetes; although larger doses (100–
150 mg/kg) are, they are also associated with harmful side
effects [11, 35]. Nephrotoxicity and hepatotoxicity are some
of the major disadvantages of high-dose STZ; nonetheless,
STZ-induced diabetic monkeys usually remain diabetic and
insulin dependent for years, with no significant endogenous
C-peptide release even after glucose stimulation and
histologic evidence of only a few insulin-staining cells
surviving in the pancreas [11]. There is interspecies
variation in the effectiveness of STZ also due to the
different expression of low-affinity glucose transporter 2
(GLUT-2), which is the receptor through with STZ accesses
the β cells but also, to a lower extent, renal and hepatic
cells, where this receptor is also expressed. STZ could thus
cause hepato- and nephrotoxicity.
There are other important variables that can influence the
effectiveness of STZ after intravenous administration, such
as the age of the NHPs and an intrinsic sensitivity of the β
cells to the drug [36]. Post-STZ hyperglycemia is typically
the main indication that a diabetic status has been
established; however, C-peptide levels are usually measured
for a correct diagnosis. Primate C-peptide levels less than
0.9 ng/mL are considered sufficient to indicate a diabetic
status; however, our group has established that diabetes is
durable when at least a 75% reduction in C-peptide levels
post STZ is recorded [35, 37] and a negative response (lack
of C-peptide increase) after a challenge is confirmed [4,
37]. The intravenous glucose tolerance and arginine
stimulation tests are the most used challenge tests. The
diabetic status of NHPs can be further evaluated by
checking the variations in hemoglobin A1c (HbA1c) levels
[38]. The effect of STZ on β cells can also be evaluated by
histologic examination of pancreatic biopsies, but this
requires a surgical procedure and, because some residual
insulin immunostaining is always present, it is difficult to
quantify the real extent of the damage. The combination of
hyperglycemia, insulin dependence, failure to increase C-
peptide levels after stimulation, and increase in HbA1c
levels allows for a correct diagnosis of STZ-induced
diabetes.
Porcine Islets XenoTx Survival in NHPs
Currently, pig islet xenoTx studies in NHPs have been
reported by 15 institutions, including transplantation in
nondiabetic (Table 1)[ 19, 23, 39–43] and diabetic
recipients (Table 2)[ 13], [15￿, 16, 17, 38, 39, 42, 44–48].
However, prolonged restoration (>3 months) of insulin
independence after porcine islet xenoTx in NHPs with
spontaneous, chemical, or surgically induced diabetes has
only been reported by a few groups [16, 17, 46–48], with
xenograft survival exceeding 6 months in even fewer cases.
These promising findings indicate that pig islet xenoTx has
the potential to cure diabetes in NHPs, and provide a strong
rationale to envision clinical future applications.
Long-term insulin independence has been achieved
using different strategies, such as: 1) intraportal infusion
of wild-type adult and neonatal pigs islet in immunosup-
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islets from adult α-1,3-Gal-deficient animals transgenic for
human membrane cofactor protein (CD46) in STZ-diabetic
immunosuppressed NHPs [15￿, 46]; 3) implantation of
embryonic pig pancreatic precursor tissue in STZ-diabetic
animals [48]; 4) intraperitoneal transplantation of micro-
encapsulated adult pig islets in nonimmunosuppressed
spontaneously diabetic NHPs; and 5) subcutaneous implan-
tation of a monolayer of encapsulated adult islets on a
collagen matrix in a nonimmunosuppressed NHP [48,
49￿￿]. The choice of the anatomical site for the implantation
of porcine islets in the recipient is a crucial aspect in
xenoTx. The current clinical practice is to put islets into the
liver, through the portal vein. However, it has now been
recognized that this implantation site has several character-
istics that can hamper islet engraftment and survival, such
as low oxygen tension, an active innate immune system,
and induction of a strong inflammatory response (the
immediate blood-mediated inflammatory reaction [IBMIR])
[50] and that is therefore associated with considerable early
graft loss. When placed under the renal capsule, islets are
more protected from immediate destruction, but ischemic
injury can be a major problem in this site. Although it is a
very successful site in rodent recipients, unfortunately, low
or no porcine (graft) C-peptide production has been
reported after subcapsular transplantation of islets in NHPs
[19, 43].
Porcine islet transplantation in the subcutaneous tissue
showed triggering of early inflammatory responses,
whereas encapsulated porcine islets in a macrodevice
inserted under the skin more successfully controlled
d i a b e t e sf o ru pt o6m o n t h s ,e v e ni nt h ea b s e n c eo f
immunosuppression [49￿￿]. In a pig alloTx model, it has
been shown that when islets are transplanted into the
gastric submucosal space, a site where direct contact with
the blood stream is delayed, while a rich arterial blood
supply for delivery of oxygen and nutrients is maintained,
the graft can survive [30]. This site has several character-
istics that could favor islet Tx and islet engraftment: a
similar embryonic origin as the pancreas, a delayed direct
contact with the blood stream while a rich arterial blood
supply for delivery of oxygen and nutrients is maintained,
and venous drainage of produced insulin into the portal
vein blood stream for direct utilization in the liver; a
Table 1 Pig islet cell xenografts in nondiabetic nonhuman primates
Donor
pig age
Recipient Site of
transplantation
Immunosuppression, encapsulation,
and/or genetic engineering
Maximum
graft survival
Reference
Adult Cyno (n=8) Intraportal None (n=7) Pretreatment with sCR1 (n=1) Post-transplant follow-up
for 60 min only
Bennet et al. [23]
Adult Baboon (n=2) Intraportal Whole-body and thymic irradiation+A TG+
EIA+MMF+CsA+CVF+steroids+αCD154
>14 d and <28 d Buhler et al. [39]
Adult Baboon (n=4) Intraportal A TG+CsA or LF−195+MMF+steroids 2 d Cantarovich
et al. [40]
Cyno (n=1)
Adult Group 1 Renal subcapsular
and intraportal
Group 1: (cyno) CP+CsA+steroids
(rhesus) A TG+α−IL−2R+CsA; steroids
Group 1: 11 d Rijkelijkhuizen
et al. [41]
Cyno (n=4)
Rhesus (n=4)
Group 2 Group 2: A TG+α−IL−2R+CsA; steroids Group 2: 53 d
Rhesus (n=4)
Adult Rhesus (n=2) Intraportal None > 3 d Kirchhof et al.
[42]
Adult Cyno (n=15) Renal subcapsular Group 1 (n=12): encapsulation Group 1: < 180 d Dufrane et al.
[43]
Group 2 (n=2): no encapsulation Groups 2 & 3: < 7 d
Group 3 (n=1): empty capsule
Fetal Cyno (n=5) Renal subcapsular Group 1: no immunosuppression Group 1: < 7 d Mandel [19]
Group 2: CsA+steroids+CP or BQR Group 2: > 40 d
Effects of donor pig age, recipient species, and immunotherapeutic strategy on maximum islet xenograft survival.
α-IL-2R anti-interleukin 2 receptor antibody; ATG anti-thymocyte globulin; BQR brequinar; CP cyclophosphamide; CsA cyclosporin A; CVF
cobra venom factor; Cyno cynomolgus; EIA extracorporeal immunoadsorption; LF-195 deoxyspergualin analogue; MMF mycophenolate mofetil;
sCR1 soluble complement receptor 1; d days.
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Curr Diab Rep (2011) 11:402–412 407clinical advantage is that transplantation can be performed
endoscopically and endoscopic biopsies of the transplanted
islets can be carried out.
Immunological Response to Transplanted Islets
The numerous preclinical studies of pig-to-NHP islet
xenoTxs have offered important insights into the immune
mechanisms and the pathways involved in causing graft
damage. The source of pig islets, the microenvironment at
the implantation site, and the immunosuppressive therapy
significantly affect engraftment and rejection of xenogeneic
islets. Pig islet xenografts, where pig islets were isolated
from wild-type pigs, can survive for weeks and months in
NHP recipients; this indicates that they do not undergo
hyperacute rejection as, instead, it occurs in vascularized
organ transplantations. In this study neither increases in
Gal-specific IgG or IgM circulating antibody levels nor
IgG/IgM with associated C9 deposition on islets were
observed [17]. When present, the humoral response is
mainly characterized by anti-Gal antibody production. Anti-
Gal antibodies are natural preformed antibodies directed
against pig epitopes in humans and old-world monkeys.
However, the Gal epitope is expressed only on 5% of adult
islets and on 11% of NPI cells. The use of GT-KO pigs (in
association with the human CD46 transgenes) as pig islet
donors did not show a substantial protective effect toward
early islet loss, suggesting that perhaps antibody binding to
non-Gal antigens would likely be a more potent complement
activator [16, 17, 23]. In some studies, considerable IgM and
moderate-to-strong C3, C5, and C9 deposition were present
on islet surface 2 to 3 days after xenoTx [39–41]. Rejection
of pig islets in NHPs is probably a result of a combination of
innate responses, evidenced by macrophage infiltration and
antibody- and complement-mediated injury, followed by a
major T -cell response.
More potent immunosuppressive regimens have been
used to protect wild-type pig islets from rejection [17],
whereas the introduction of transgenic pigs expressing
graft-protecting factors has been shown to require a less
toxic immunosuppressive protocol [15￿].
Regarding pig islet infusion into the portal vein of NHP ,
this is associated with a considerable early graft loss,
regardless of immune rejection. This loss is not just due to
antibody-mediated complement activation, but it involves
the nonspecific response IBMIR [51]. The mechanisms
behind early graft loss remain poorly understood; it is in
part the result of tissue factor production [52]a n d
expression in the pancreatic cells. Recent data point to a
relatively underestimated role for natural antibodies, com-
plement, and coagulation [53], and platelet binding to the
islets surface and leukocyte infiltration have been demon-
strated. Triggering of numerous and not mutually exclusive
pathologic events after contact of islets with xenogeneic
blood is certainly the answer; despite the substantial loss of
islet mass (estimated up to 60% to 80%) in the early phase
post-transplantation due to IBMIR, data suggest that a
sufficient islet mass survive, achieving and maintaining
normoglycemia for months in NHP recipients.
Future Directions for Pig Islets XenoTx
Pig islet xenoTx shows important, but not insurmountable
limitations, even if recent accomplishments in preclinical
pig-to-NHP model hold great promises and may have future
implications. Concerning preclinical animal models of islet
xenoTx there are some relevant considerations on species-
specific glucose metabolism. For instance, pigs and humans
share blood glucose levels in similar concentrations,
whereas nondiabetic monkeys exhibit lower unstimulated
blood glucose. Endogenous C-peptide levels in monkeys
are in higher ranges than in humans, and substantially
higher than in pigs. When porcine islets engraft in diabetic
NHPs they need to adapt to the higher metabolic demands
of their recipients. This results in new cutoff parameters of
glucose metabolism associated with good graft islet
function, intermediate between donor and recipient base-
lines [37]. We may envision that, based on the metabolic
differences between humans and monkeys, humans and
pigs, porcine islets would perform more efficiently in
humans than in monkeys. Nonetheless, to pursue the use
of porcine islets in preclinical as well as clinical models it is
necessary to modify the immunosuppressive protocols and
to evaluate agents that can be substitutes for anti-CD154
antibodies, critical and effective components of major
studies [16, 17, 46] because of their thromboembolic effect.
Preliminary studies suggest that antagonistic anti-CD40
monoclonal antibodies could be equally effective when
combined with IL-2R antibodies, CD28 antagonists, and
sirolimus. Several other immunosuppressant agents are
currently under investigation [54].
In the future, immunosuppressive molecules should be
selected based on their ability to facilitate negative
vaccination systems during the pretransplantation phase
by administration of donor antigen to the recipient. The
immunological obstacles to xenoTx are significant. Away
to reduce the immune response after implantation of pig
islet cells in the recipient is the use of transgenic animals.
Good results using pigs expressing hCD46 (a human
complement-regulatory protein) suggest that protection
from complement activation is beneficial to survival of
the graft (Fig. 1)[ 15￿]. Furthermore, the inhibition of the T-
cell–mediated immune response is a necessary component
to prevent rejection following xenoTx. The generation of
408 Curr Diab Rep (2011) 11:402–412transgenic pigs producing cytotoxic T lymphocyte-
associated antigen (CTLA4) antibodies may also be useful
in prolonging graft acceptance [55].
A large number of islet product-directed strategies are
currently under investigation to allow minimal immuno-
suppressive treatment. These include pretransplant islet
culture in the presence of mitomycin C to upregulate
transforming growth factor-β production of islets [56],
surface heparinization, pegylation [57]o fi s l e t s ,a n d
transfection with immunorepellant SDF-1. Alginate-
encapsulated islets have also been proposed to attenuate
antibody and T-cell contact. Optimization of encapsulation
protocols may prove to be a successful approach, as
promising results indicate [49￿￿, 58]. All these strategies
Fig. 1 a, Blood glucose (BG)
(solid lines) and exogenous
insulin (broken line) profiles in a
streptozotocin-diabetic recipient
of porcine islet graft (M7273).
After porcine xenotransplantation
no exogenous insulin is required
to maintain BG levels lower than
5m m o l / L( red line)f o r1y e a r .
b, In the same animal, primate
C-peptide (solid lines) and pig
(graft) C-peptide (broken line)
levels confirm, respectively, the
diabetic status (primate
C-peptide) and the positive effect
of the pig islet transplantation
(Tx) (pig C-peptide) [15￿].
Curr Diab Rep (2011) 11:402–412 409share the central objective of creating an immunoprivileged
environment at the islet implantation site. Integrating
controlled release of immunoregulatory, cytoprotective,
and proangiogenic factors together with the use of bioscaf-
folds, microspheres and nanoparticles [58, 59] could be key
to success.
The potential for porcine endogenous retroviruses (PERV)
to harm a recipient of pig tissue has been a concern. These
potential risks are now considered to be much less significant
sinceactivationofPERVcanbepreventedbysmallinterfering
RNA technology [60]. Nevertheless, regulatory requirements
will be necessary to monitor and reduce the risk of
contracting xenozoonosis in xenoTx.
Conclusions
Building on the remarkable recent progress in the preclinical
pig-to-NHP model, it appears that adult porcine islets have the
best potential, from both a logistic and immunologic point of
view, to reverse diabetes in NHPs and furthermore in humans.
The simultaneous development of suitable sources of geneti-
cally modified pigs and more resistant-engineered pig islets,
together with the establishment of clinically applicable
immunosuppressiveregimens,couldbetranslatedintotangible
benefits for patients with T1D in the very near future.
However, questions remain and detailed problems need to be
adequately addressed.
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